Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VH4524184 Bioavailability, Food Effect, and DDI Study
NCT07066722Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VH4524184 in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoint: Maximum plasma concentration for VH4524184. Started Jul 2025; status: completed.
02
Drugs
VH4524184
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07066722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07066722.